TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Regional myocardial function (PSSR and PDSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infection development
Endpoint domain: Adverse events/effects
Primary endpoint: Low density lipoprotein (LDL) cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitrite/nitrate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Menstrual pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NSL difference scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MAC-Q difference scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total program costs for HIV interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean FBL (Fluid Blood Loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time ratio of cumulative hours with a difference in CBS score of ≥ 4 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time ratio of cumulative hours with a difference in CBS score of ≥ 8 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative amount of midazolam used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regulatory T cells increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of hospital-acquired infections
Endpoint domain: Adverse events/effects
Primary endpoint: hand/foot reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: falls risk
Endpoint domain: Adverse events/effects
Primary endpoint: lightening efficacy for light TST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: periods of treatment shortened
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neonatal outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average minimum core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcomes after ICH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %necrotic core (NC) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: thin-cap fibroatheroma (TCFA) prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: P(A‐a) DO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood concentrations of sICAM‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean diurnal variation of PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with exacerbations of asthma
Endpoint domain: Adverse events/effects
Primary endpoint: psychosocial morbidity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: goal performance and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in UI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum cystometric capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Antibody responses to hepatitis B vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-7 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the concentration-time curve extrapolated to infinity (AUC∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of stage 3 and 4 sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: frequency and severity of narcolepsy symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Bayley's MDI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical scar appearance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total number of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: usual fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Time needed to resume daily activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean plasma cortisol levels suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: dietary improvement in macronutrients and micronutrients intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hours per study day spent agitated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall occurrence of ischemic stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: all causes of death
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of finder needle passes into the IJV on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative success rates on the first 3 attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Pelvic Organ Prolapse Quantification System stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevation of bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevation of rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NO-mediated vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 8-F(2) isoprostane plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: weaning duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reintubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake rates of SBI package requests
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Utilization rates of SBI package
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Healing rates of epithelium and hard tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in sensory modalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Linear growth (LAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stunting prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Fatigue Score (FS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mental Fatigue Score (FS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Total Fatigue Score (FS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: requirement for supplemental analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of analgesic doses required in 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FAS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital survival rate
Endpoint domain: Mortality/survival
Primary endpoint: time of showing purposeful movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emergence from anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: readiness to be discharged
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lag time suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary vascular resistance during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: H-reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MVIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity measured by 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic function restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rectal temperature decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance cycled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preventable ADEs
Endpoint domain: Adverse events/effects
Primary endpoint: Taste preference for cefdinir
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Smell preference for cefdinir
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of proliferating cells in the upper 40% of crypts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zinc deficiency prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Iron deficiency reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: externalizing behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum total and LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma PS concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hospitalization for bleeding or thromboembolism
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: mean reduction of retinochoroidal lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual acuity (VA) after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall recurrence rate after 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Disability at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic pain status at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intubation difficulty score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of laryngoscopy and intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: post-operative peak troponin release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency and severity of IFN‐α‐associated depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: motor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical motor status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uneventful recovery
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative pyrexia
Endpoint domain: Adverse events/effects
Primary endpoint: apoptotic cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perisinusoidal fibrosis degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum tHcy concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: aortic root growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lung Injury Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance and accuracy with hand-washing policy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: reduction in safety problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hSBA titers ≥1:8 for MenC, MenW and MenY
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hSBA titers ≥1:8 for MenA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccine responses 1-month post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Health Utility (HU) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Microvascular endothelial reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of ventricular fibrillation on aortic unclamping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LNG Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EE C24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median bodyweight loss at 1 month after gastrectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median bodyweight loss at 3 months after gastrectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Average treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total score for RQLQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Distinction between pathologically insignificant and aggressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BCVA over 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of foveal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative Syndrome Scale total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scale for Assessment of Negative Symptoms total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esthetic result
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: couple concordance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: log cortisol: creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: accelerometer-measured daily MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in days of heroin and cocaine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant pain relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Late rectal toxicity >or= G2
Endpoint domain: Adverse events/effects
Primary endpoint: Tonus of plantar flexor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Active ROM of ankle joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Gait function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ongoing suppression of dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of reflux esophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: Esophageal acid exposition time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Interpersonal relations
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in SCORE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local anesthetic dose requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of urinary tract infection (UTI)
Endpoint domain: Adverse events/effects
Primary endpoint: Comfort of contact lens wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescein-staining corneal punctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent with blood glucose less than 70 mg/dL (TB70)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment success rate
Endpoint domain: Mortality/survival
Primary endpoint: DHI score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in attention and information processing and executive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mass of small dense LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: total LDL concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mass of high-density lipoprotein-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma concentrations of vitamin E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of alpha‐ and beta‐carotene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of lutein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in body height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who did not require platelet transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: endorsement of EHEs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in objective scores from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratings of overall improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: risk of paroxysmal atrial fibrillation (AF)
Endpoint domain: Adverse events/effects
Primary endpoint: Adoption of regular contraceptive methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: WOMAC-function score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores during colposcopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dysrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: daily opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parent satisfaction with level of involvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of cardiopulmonary events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in endometrioma size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: LDL cholesterol levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non-attendance rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: primary patency rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIBDQ-9 score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EQ-5D score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse events (AEs) of mild intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean ratios (GMRs) of Cmax and AUClast for gemigliptin and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure (IOP) at T1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Accuracy of preoperative staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentual nighttime drop in mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes